Published in N Engl J Med on April 12, 2001
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | NCT04849377
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol (2003) 2.26
The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun (2013) 2.17
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis (2011) 1.87
Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.85
Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol (2005) 1.81
HPV infections and tonsillar carcinoma. J Clin Pathol (2004) 1.76
Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol (2006) 1.76
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
HPV & head and neck cancer: a descriptive update. Head Neck Oncol (2009) 1.60
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One (2010) 1.49
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol (2012) 1.45
Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J Dent Res (2009) 1.31
Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol (2012) 1.29
Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol (2008) 1.29
Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg (2009) 1.27
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma. Head Neck Pathol (2008) 1.22
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Head and neck cancer: an evolving treatment paradigm. Cancer (2008) 1.21
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20
The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol (2006) 1.20
Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol (2014) 1.19
Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck (2010) 1.16
Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system. Head Neck Pathol (2010) 1.16
Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J (2002) 1.14
Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples. J Clin Virol (2011) 1.14
Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer (2011) 1.13
HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol (2007) 1.13
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
HPV detection methods in head and neck cancer. Head Neck Pathol (2012) 1.10
Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med (2010) 1.09
Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res (2010) 1.09
Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health (2008) 1.09
Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites. Cancer (2009) 1.09
Discussing the diagnosis of HPV-OSCC: common questions and answers. Oral Oncol (2013) 1.09
Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol (2017) 1.08
Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol (2002) 1.08
Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl (2010) 1.08
Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital (2009) 1.05
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle (2013) 1.04
The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview. Infect Agent Cancer (2011) 1.04
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study. Infect Agent Cancer (2011) 1.01
Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol (2011) 1.01
Lifetime body mass index and risk of oral cavity and oropharyngeal cancer by smoking and drinking habits. Br J Cancer (2003) 1.01
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci (2014) 0.98
High-risk human papilloma virus (HPV) and survival in patients with esophageal carcinoma: a pilot study. BMC Cancer (2006) 0.98
Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol (2005) 0.97
Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005. PLoS One (2012) 0.97
Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med (2008) 0.97
Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev (2008) 0.96
Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 0.96
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int J Cancer (2012) 0.94
Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer (2013) 0.94
Impact of HPV in Oropharyngeal Cancer. J Oncol (2010) 0.93
Molecular mechanisms of head and neck cancer. Expert Rev Anticancer Ther (2008) 0.91
Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am (2008) 0.91
p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer (2008) 0.90
HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol (2015) 0.90
Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol (2011) 0.89
Improving oral cancer survival: the role of dental providers. J Calif Dent Assoc (2009) 0.89
A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide. Oncologist (2013) 0.89
Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 0.89
Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. PLoS One (2014) 0.89
Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin. PLoS One (2014) 0.88
Molecular and genetic aspects of odontogenic tumors: a review. Iran J Basic Med Sci (2015) 0.88
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Cell Death Dis (2014) 0.88
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. PLoS One (2010) 0.87
History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med (2015) 0.87
Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 2. Head Neck Pathol (2009) 0.87
HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol (2015) 0.87
HPV infection in esophageal squamous cell carcinoma and its relationship to the prognosis of patients in northern China. ScientificWorldJournal (2014) 0.87
Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck (2012) 0.87
Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. PLoS One (2013) 0.87
Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma. Mol Cancer (2013) 0.86
Epithelial maturation and molecular biology of oral HPV. Infect Agent Cancer (2009) 0.86
An update on oral human papillomavirus infection. Indian J Sex Transm Dis (2013) 0.85
Sensitive HPV detection in oropharyngeal cancers. BMC Cancer (2009) 0.85
A multiscale and multiparametric approach for modeling the progression of oral cancer. BMC Med Inform Decis Mak (2012) 0.85
HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital (2014) 0.85
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 0.85
Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center. Eur Arch Otorhinolaryngol (2014) 0.84
Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84
Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer (2014) 0.84
High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis (2003) 0.83
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49
Helicobacter pylori infection and gastric lymphoma. N Engl J Med (1994) 10.26
European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr (2002) 8.77
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 6.23
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol (1994) 4.89
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol (1999) 3.19
Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17
Coeliac disease--associated disorders and survival. Gut (1994) 3.13
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J (1987) 2.84
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Survival of cancer patients in Finland 1955-1994. Acta Oncol (1999) 2.67
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J (1988) 2.66
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell (1989) 2.52
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet (1994) 2.50
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol (2001) 2.48
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis (1993) 2.45
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia (2011) 2.43
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ (1997) 2.41
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Social class as a prognostic factor in breast cancer survival. Cancer (1990) 2.37
Underreporting of energy intake in repeated 24-hour recalls related to gender, age, weight status, day of interview, educational level, reported food intake, smoking habits and area of living. Public Health Nutr (2001) 2.37
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst (2000) 2.34
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol (1997) 2.30
Bovine papilloma virus-transformed cells contain multiple E2 proteins. Proc Natl Acad Sci U S A (1988) 2.29
Risk of cancer in Finnish children living close to power lines. BMJ (1993) 2.29
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood (2001) 2.26
Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology (2000) 2.25
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med (1989) 2.25
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia (2007) 2.23
Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry (2001) 2.23
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ (1999) 2.18
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol (1998) 2.12
Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol (2000) 2.09
A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes (1995) 2.08
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08
A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control (1999) 2.08
From cross-tabulations to multipurpose exposure information systems: a new job-exposure matrix. Am J Ind Med (1998) 2.07
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med (1997) 2.06
Changes in amino acids, ammonium, and coagulation factors after transcervical resection of the endometrium with a glycine solution used for uterine irrigation. Am J Obstet Gynecol (1995) 2.04
Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer (1988) 2.02
Progression of asbestosis predicts lung cancer. Chest (1998) 2.02
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol (1991) 2.00
Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. Aliment Pharmacol Ther (2014) 2.00
Genetic assignment of multiple E2 gene products in bovine papillomavirus-transformed cells. J Virol (1989) 1.97
Recent adverse trends in semen quality and testis cancer incidence among Finnish men. Int J Androl (2011) 1.96
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
Humoral immunity against Francisella tularensis after natural infection. J Clin Microbiol (1985) 1.94
Indoor radon exposure and risk of lung cancer: a nested case-control study in Finland. J Natl Cancer Inst (1996) 1.93
Epidemiological study of nephropathia epidemica in Finland 1989-96. Scand J Infect Dis (1999) 1.93